Letter to the Editor

Is microbiome a target for the management of allergy associated diseases in children?

Dear Editor,

We have read with interest the recent review on the management of allergy associated diseases in children¹. In the last few decades, allergy associated diseases like allergic rhinitis, asthma, food allergy, etc. are progressively increasing worldwide. Changes in personal or maternal smoking habits, types of dwelling, adaptation to Western dietary habits, reduced infection rates, decreased family size and hygiene, air pollution, work exposure or changed microbiome due to occidental style of life might be the possible causes². In case of food allergy, one of the most prominent public health problems, especially in children, allergens like egg, tree nuts and cow milk are the most commonly reported culprits. In this context, Zhu et al¹. reported various strategies for the management, like oral immune therapy and use of hypo-allergenic diet, but the curative therapy is far. Regarding allergic asthma, the authors discussed the role of immunotherapy-based treatments, as oral immunotherapy³. For allergic rhinitis MP-AzeFlu, an intranasal antihistamine, has been reported efficient⁴. The pathogenesis of atopy is multifactorial and remains unclear. Its development involves multiple genes, an altered innate and adaptive immune response, epidermal epithelial dysfunction and is influenced by several environmental risk factors. The actual historical period is characterized for the life sciences from an exciting and growing interest for the role of the microbiota on human health⁵. Alterations in the gut microbiome, defined dysbiosis, affect the immune system balance, contributing to the natural courses of several diseases⁶. Infancy has been identified as important and vulnerable period in the development of the gut microbiome, which shapes an individual's disposition to atopy⁷. Since the possible application of probiotics to the therapeutic management of allergic diseases has been the focus of several recent studies^{7,8}, it would be interesting to discuss in future papers this potential promising therapeutic strategy.

Financial disclosure No financial support to declare.

Conflict of interest

The authors declare no conflicts of interest.

References

- ZHU L, ZHU F, ZHANG ZK. Recent advances in the management of allergy associated diseases in children. Eur Rev Med Pharmacol Sci 2018; 22: 7582-7587.
- 2) RIBALDONE DG, FAGOONEE S, COLOMBINI J, SARACCO G, ASTEGIANO M, PELLICANO R. Helicobacter pylori infection and asthma: is there a direct or an inverse association? A metaanalysis. World J Meta-Anal 2016; 4: 63-68.
- 3) MARTINEZ FD, VERCELLI D. Asthma. Lancet 2013; 382: 1360-1372.
- 4) CARR W, BERNSTEIN J, LIEBERMAN P, MELTZER E, BACHERT C, PRICE D, MUNZEL U, BOUSOUET J. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012; 129: 1282-1289.

Corresponding Author: Davide Giuseppe Ribaldone, MD; e-mail: davrib_1998@yahoo.com

8061

- 5) GIBINO G, LANIRO G, CAMMAROTA G, GASBARRINI A. The gut microbiota: its anatomy and physiology over a lifetime. Minerva Gastroenterol Dietol 2017; 63: 329-336.
- 6) RIBALDONE DG, PELLICANO R, ACTIS GC. Inflammation: a highly conserved, Janus-like phenomenon-a gastroenterologist' perspective. J Mol Med (Berl). 2018 Jul 9. doi: 10.1007/s00109-018-1668-z. [Epub ahead of print]
- LEE SY, LEE E, PARK YM, HONG SJ. Microbiome in the gut-skin axis in atopic dermatitis. Allergy Asthma Immunol Res 2018; 10: 354-362.
- DI PIERRO F, BASILE I, DANZA ML, VENTURELLI L, CONTINI R, RISSO P, COLOMBO M. Use of a probiotic mixture containing bifidobacterium animalis subsp. lactis BB12 and enterococcus faecium L3 in atopic children. Minerva Pediatr 2018; 70: 418-424.

D.G. Ribaldone¹, M. Vernero², R. Pellicano³

¹Department of Surgical Sciences, University of Turin, Turin, Italy ²First Department of Internal Medicine, University of Pavia, Pavia, Italy ³Unit of Gastroenterology, Molinette Hospital, Turin, Italy

